The Globe and Mail reports in its Wednesday, May 10, edition that National Bank Financial analyst Tal Woolley has reiterated his "sector perform" recommendation for Extendicare. The Globe's David Leeder writes that Mr. Woolley bumped his share target ahead by 50 cents to $7.50, matching the consensus. Mr. Woolley notes that Extendicare posted better-than-expected first quarter results. This led Mr. Woolley to raise his valuation for Extendicare. He sees potential gains made possible by provincial long-term care funding changes. As well, Mr. Woolley likes Extendicare's "changing business mix, growth prospects and leverage." Mr. Woolley says in a note: "We would expect Extendicare shares to track the market near term. The closing of the Axium/Revera deals still lies ahead in Q3, which will change Extendicare's asset mix/earnings profile again. Until we see better earnings visibility, we cannot envision shares meaningfully outperforming the market. We note, however, that Extendicare remains active on its buyback, which could provide some downside protection while the last of the COVID-era volatility diminishes." The Globe reported on March 7 that RBC rated Extendicare "sector perform." It was then worth $6.51.